Differences in nephrotoxicity risk and renal effects among anti‐viral therapies against hepatitis B
Alimentary Pharmacology & Therapeutics2014Vol. 41(3), pp. 310–319
Citations Over TimeTop 10% of 2014 papers
Seyfettin Köklü, Murat Gülşen, Yaşar Tuna, Hayretdin Köklü, Özgür Haki Yüksel, Münevver Demir, Rahmet Güner, Zeynal Doğan, Metin Küçükazman, Orhan Kürşat Poyrazoğlu, Murat Bıyık, Nilüfer Acet Öztürk, T. Aydoğan, Şahin Çoban, Orhan Kocaman, Feride Sapmaz, Suut Göktürk, Cebrail Karaca, Aylin Demırezer, Alpaslan Tanoğlu, Beytullah Yıldırım, Akif Altınbaş, Burçin Meryem Atak Tel, Arif Coşar, Erhan Alkan, Other collaborators
Abstract
Although tenofovir caused a decline in GFR, differences between the anti-viral agents do not appear to be so impressive. In patients with and without renal risk factors at baseline, there is no impact of anti-virals, including tenofovir.
Related Papers
- → Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy(2008)45 cited
- → Redetection of HBV lamivudine‐resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues(2007)4 cited
- Entecavir : A review(2006)
- → The effectivness of entecavir in chronic hepatitis B in patients resistant to lamivudine and adefovir(2008)
- → Detection of Mutations Resistant to Lamivudine or Adefovir in HBV and Its Management(2013)